

# Francisco Marin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1075217/publications.pdf>

Version: 2024-02-01

253  
papers

8,525  
citations

41323

49  
h-index

54882

84  
g-index

262  
all docs

262  
docs citations

262  
times ranked

8694  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Atrial Fibrillation Better Care (ABC) Pathway and Clinical Outcomes in Patients with Atrial Fibrillation: the Prospective Murcia AF Project Phase II Cohort. <i>Journal of General Internal Medicine</i> , 2023, 38, 315-323.	1.3	2
2	Variables affecting the quality of anticoagulation in atrial fibrillation patients newly initiating vitamin K antagonists: insights from the national and multicentre SULTAN registry. <i>Europace</i> , 2022, 24, 4-11.	0.7	2
3	Number needed to treat for net effect of anticoagulation in atrial fibrillation: Real-world vs. clinical trial evidence. <i>British Journal of Clinical Pharmacology</i> , 2022, 88, 282-289.	1.1	8
4	Real-world applicability and impact of early rhythm control for European patients with atrial fibrillation: a report from the ESC-EHRA EORP-AF Long-Term General Registry. <i>Clinical Research in Cardiology</i> , 2022, 111, 70-84.	1.5	25
5	Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 202-210.	0.7	9
6	Novel insights in the relationship of gut microbiota and coronary artery diseases. <i>Critical Reviews in Food Science and Nutrition</i> , 2022, 62, 3738-3750.	5.4	14
7	Antiplatelet therapy and outcome in COVID-19: the Health Outcome Predictive Evaluation Registry. <i>Heart</i> , 2022, 108, 130-136.	1.2	49
8	Clinical utility and prognostic implications of the novel 4S-AF scheme to characterize and evaluate patients with atrial fibrillation: a report from ESC-EHRA EORP-AF Long-Term General Registry. <i>Europace</i> , 2022, 24, 721-728.	0.7	12
9	Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation. <i>Clinical Research in Cardiology</i> , 2022, 111, 1040-1047.	1.5	6
10	Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF Long-Term General Registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13745.	1.7	10
11	Clinical implications of diabetes mellitus in patients with acute coronary syndrome: Prognostic role and use of new P2Y12 receptor inhibitors. <i>Diabetes Research and Clinical Practice</i> , 2022, 184, 109215.	1.1	0
12	Assessment and mitigation of bleeding risk in atrial fibrillation and venous thromboembolism: A Position Paper from the ESC Working Group on Thrombosis, in collaboration with the European Heart Rhythm Association, the Association for Acute CardioVascular Care and the Asia-Pacific Heart Rhythm Society. <i>Europace</i> , 2022, 24, 1844-1871.	0.7	11
13	Cardiac troponins and adverse outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EORP atrial fibrillation general long-term registry. <i>European Journal of Internal Medicine</i> , 2022, 99, 45-56.	1.0	5
14	Impact of malignancy on outcomes in European patients with atrial fibrillation: A report from the ESC-EHRA EURObservational research programme in atrial fibrillation general long-term registry. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13773.	1.7	6
15	Relation of the Atrial Fibrillation Better Care (ABC) Pathway™ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists. <i>Journal of Personalized Medicine</i> , 2022, 12, 487.	1.1	4
16	Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights from the EMIR study. <i>European Journal of Clinical Investigation</i> , 2022, 52, e13788.	1.7	5
17	Prediction of ischemic stroke in different populations: a comparison of absolute stroke risk and CHA2DS2-VASc in real-world and clinical trial patients. <i>European Journal of Internal Medicine</i> , 2022, 98, 122-124.	1.0	1
18	Relationship between temporal rhythm-based classification of atrial fibrillation and stroke: real-world vs. clinical trial. <i>Journal of Thrombosis and Thrombolysis</i> , 2022, , 1.	1.0	0

#	ARTICLE	IF	CITATIONS
19	Diagnostic and therapeutic potential of miRNAs in cardiovascular disease: a clinical reality?. Revista Espanola De Cardiologia (English Ed ), 2022, , .	0.4	0
20	Predicting heart failure in atrial fibrillation patients: What about using biomarkers?. American Heart Journal, 2022, 251, 32-32.	1.2	0
21	Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIA Registry. Frontiers in Cardiovascular Medicine, 2022, 9, 856222.	1.1	4
22	Impact of diabetes on the management and outcomes in atrial fibrillation: an analysis from the ESC-EHRA EORP-AF Long-Term General Registry. European Journal of Internal Medicine, 2022, 103, 41-49.	1.0	5
23	Chronic Oral Anticoagulation Therapy and Prognosis of Patients Admitted to Hospital for COVID-19: Insights from the HOPE COVID-19 Registry. International Journal of Clinical Practice, 2022, 2022, 1-9.	0.8	1
24	Stroke and Thromboembolism in Warfarin-Treated Patients with Atrial Fibrillation: Comparing the CHA2DS2-VASc and GARFIELD-AF Risk Scores. Thrombosis and Haemostasis, 2021, 121, 1107-1114.	1.8	4
25	Relation of outcomes to ABC (Atrial Fibrillation Better Care) pathway adherent care in European patients with atrial fibrillation: an analysis from the ESC-EHRA EORP Atrial Fibrillation General Long-Term (AFGen LT) Registry. Europace, 2021, 23, 174-183.	0.7	74
26	Clinical profile and prognosis in patients on oral anticoagulation before admission for COVID-19. European Journal of Clinical Investigation, 2021, 51, e13436.	1.7	45
27	The interpretation of CHA2DS2-VASc score components in clinical practice: a joint survey by the European Heart Rhythm Association (EHRA) Scientific Initiatives Committee, the EHRA Young Electrophysiologists, the Association of Cardiovascular Nursing and Allied Professionals, and the European Society of Cardiology Council on Stroke. Europace, 2021, 23, 314-322.	0.7	9
28	Comparison of Aortic Gradient and Ventricular Mass after Valve Replacement for Aortic Stenosis with Rapid Deployment, Sutureless, and Conventional Bioprostheses. Cardiology, 2021, 146, 656-666.	0.6	2
29	Gut Microbiota and the Quality of Oral Anticoagulation in Vitamin K Antagonists Users: A Review of Potential Implications. Journal of Clinical Medicine, 2021, 10, 715.	1.0	9
30	Impact of frailty and atrial fibrillation in elderly patients with acute coronary syndromes. European Journal of Clinical Investigation, 2021, 51, e13505.	1.7	3
31	Comments on the 2020 ESC/EACTS guidelines for the management of atrial fibrillation. Revista Espanola De Cardiologia (English Ed ), 2021, 74, 378-383.	0.4	2
32	Comentarios a la guÃa ESC/EACTS 2020 sobre el diagnÃstico y tratamiento de la fibrilaci3n auricular. Revista Espanola De Cardiologia, 2021, 74, 378-383.	0.6	2
33	Thromboembolic and bleeding events with rivaroxaban in clinical practice in Spain: impact of inappropriate doses (the EMIR study). Journal of Comparative Effectiveness Research, 2021, 10, 583-593.	0.6	15
34	Direct-acting oral anticoagulants use prior to COVID-19 diagnosis and associations with 30-day clinical outcomes. Thrombosis Research, 2021, 205, 1-7.	0.8	18
35	Prediction of Residual Stroke Risk in Anticoagulated Patients with Atrial Fibrillation: mCARS. Journal of Clinical Medicine, 2021, 10, 3357.	1.0	4
36	Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. International Journal of Molecular Sciences, 2021, 22, 7113.	1.8	7

#	ARTICLE	IF	CITATIONS
37	Renin-angiotensin system inhibitors effect before and during hospitalization in COVID-19 outcomes: Final analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for) Tj ETQq1 1 0.784314.2021/07/10/10.1007/s12275-021-00100-0	0.784314	10
38	In-hospital outcomes of mechanical complications in acute myocardial infarction: Analysis from a nationwide Spanish database. <i>Cardiology Journal</i> , 2021, 28, 589-597.	0.5	8
39	Prognosis Impact of Diabetes in Elderly Women and Men with Non-ST Elevation Acute Coronary Syndrome. <i>Journal of Clinical Medicine</i> , 2021, 10, 4403.	1.0	5
40	Efficacy and safety of direct-acting oral anticoagulants compared to vitamin K antagonists in COVID-19 outpatients with cardiometabolic diseases. <i>Cardiovascular Diabetology</i> , 2021, 20, 176.	2.7	10
41	Carga de comorbilidad y beneficio de la revascularización en ancianos con síndrome coronario agudo. <i>Revista Española De Cardiología</i> , 2021, 74, 765-772.	0.6	14
42	Relationship between multimorbidity and outcomes in atrial fibrillation. <i>Experimental Gerontology</i> , 2021, 153, 111482.	1.2	16
43	OUP accepted manuscript. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2021, , .	1.4	1
44	Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. <i>BMC Medicine</i> , 2021, 19, 256.	2.3	22
45	Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-Term General Registry. <i>European Journal of Clinical Investigation</i> , 2021, , e13709.	1.7	0
46	Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. <i>Frontiers in Cardiovascular Medicine</i> , 2021, 8, 787235.	1.1	4
47	Diagnosis and management of left atrial appendage thrombus in patients with atrial fibrillation undergoing cardioversion or percutaneous left atrial procedures: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2020, 22, 162-169.	0.7	26
48	“Real-world” observational studies in arrhythmia research: data sources, methodology, and interpretation. A position document from European Heart Rhythm Association (EHRA), endorsed by Heart Rhythm Society (HRS), Asia-Pacific HRS (APHRS), and Latin America HRS (LAHRS). <i>Europace</i> , 2020, 22, 831-832.	0.7	18
49	Treatment strategies for patients with atrial fibrillation and anticoagulant-associated intracranial hemorrhage: an overview of the pharmacotherapy. <i>Expert Opinion on Pharmacotherapy</i> , 2020, 21, 1867-1881.	0.9	3
50	Pilot Study on the Role of Circulating miRNAs for the Improvement of the Predictive Ability of the 2MACE Score in Patients with Atrial Fibrillation. <i>Journal of Clinical Medicine</i> , 2020, 9, 3645.	1.0	11
51	Factor XI, much more than an innocent observer. <i>Journal of Thrombosis and Haemostasis</i> , 2020, 18, 3172-3173.	1.9	1
52	Utilizing biomarkers associated with cardiovascular events in atrial fibrillation: informing a precision medicine response. <i>Expert Review of Precision Medicine and Drug Development</i> , 2020, 5, 331-345.	0.4	0
53	A nurse-led atrial fibrillation clinic: Impact on anticoagulation therapy and clinical outcomes. <i>International Journal of Clinical Practice</i> , 2020, 74, e13634.	0.8	13
54	Comorbidity burden and revascularization benefit in elderly patients with acute coronary syndrome. <i>Revista Española De Cardiología (English Ed )</i> , 2020, 74, 765-772.	0.4	6

#	ARTICLE	IF	CITATIONS
55	Particulate Matter and Temperature: Increased Risk of Adverse Clinical Outcomes in Patients With Atrial Fibrillation. Mayo Clinic Proceedings, 2020, 95, 2360-2369.	1.4	8
56	Relationship of adverse events to quality of anticoagulation control in atrial fibrillation patients with diabetes: real-world data from the FANTASIA Registry. Annals of Medicine, 2020, 52, 300-309.	1.5	7
57	Predicting Adverse Events beyond Stroke and Bleeding with the ABC-Stroke and ABC-Bleeding Scores in Patients with Atrial Fibrillation: The Murcia AF Project. Thrombosis and Haemostasis, 2020, 120, 1200-1207.	1.8	41
58	Direct Anticoagulants Versus Vitamin K Antagonists in Patients Aged 80 Years or Older With Atrial Fibrillation in a "Real-world" Nationwide Registry: Insights From the FANTASIA Study. Journal of Cardiovascular Pharmacology and Therapeutics, 2020, 25, 316-323.	1.0	1
59	Impact of renal function on admission in COVID-19 patients: an analysis of the international HOPE COVID-19 (Health Outcome Predictive Evaluation for COVID 19) Registry. Journal of Nephrology, 2020, 33, 737-745.	0.9	81
60	Recommendations on antithrombotic treatment during the COVID-19 pandemic. Position statement of the Working Group on Cardiovascular Thrombosis of the Spanish Society of Cardiology. Revista Espanola De Cardiologia (English Ed ), 2020, 73, 749-757.	0.4	38
61	Atrial fibrillation in acute heart failure: A position statement from the Acute Cardiovascular Care Association and European Heart Rhythm Association of the European Society of Cardiology. European Heart Journal: Acute Cardiovascular Care, 2020, 9, 348-357.	0.4	39
62	Influence of sex on long-term prognosis in patients with atrial fibrillation treated with oral anticoagulants. Results from the prospective, nationwide FANTASIA study. European Journal of Internal Medicine, 2020, 78, 63-68.	1.0	3
63	Influence of the matrix type over the concentration of GDF-15. Journal of Investigative Medicine, 2020, 68, 1402-1404.	0.7	0
64	Impact of body mass index on outcomes in European patients with atrial fibrillation: the ESC EHRA EORP Atrial Fibrillation General Long-Term registry (AFGen LT). European Heart Journal, 2020, 41, .	1.0	0
65	European Heart Rhythm Association (EHRA) consensus document on management of arrhythmias and cardiac electronic devices in the critically ill and post-surgery patient, endorsed by Heart Rhythm Society (HRS), Asia Pacific Heart Rhythm Society (APHRS), Cardiac Arrhythmia Society of Southern Europe (CASS), and the Japanese Circulation Society (JCS). European Heart Journal, 2018, 39, 217-227.	0.7	72
66	2018 Joint European Consensus Document on the Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Cardiovascular Interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology Working Group on Thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society. Europace, 2019, 21, 192-193.	0.7	209
67	Are There Gaps in the Evidence on the Treatment of Mild Hypertension in Patients With Low Cardiovascular Risk? Response. Revista Espanola De Cardiologia (English Ed ), 2019, 72, 886.	0.4	0
68	The Use of Biomarkers in Clinical Management Guidelines: A Critical Appraisal. Thrombosis and Haemostasis, 2019, 119, 1901-1919.	1.8	57
69	Comorbidity assessment for mortality risk stratification in elderly patients with acute coronary syndrome. European Journal of Internal Medicine, 2019, 62, 48-53.	1.0	24
70	High and low on-treatment platelet reactivity to P2Y12 inhibitors in a contemporary cohort of acute coronary syndrome patients undergoing percutaneous coronary intervention. Thrombosis Research, 2019, 175, 95-101.	0.8	14
71	Refining Stroke and Bleeding Prediction in Atrial Fibrillation by Adding Consecutive Biomarkers to Clinical Risk Scores. Stroke, 2019, 50, 1372-1379.	1.0	48
72	Galectin-3 and Î²2-trace protein concentrations are higher in clinically unaffected patients with Fabry disease. Scientific Reports, 2019, 9, 6235.	1.6	1

#	ARTICLE	IF	CITATIONS
73	Association between antithrombotic treatment and outcomes at 1-year follow-up in patients with atrial fibrillation: the EORP-AF General Long-Term Registry. <i>Europace</i> , 2019, 21, 1013-1022.	0.7	47
74	Antithrombotic treatment in patients with atrial fibrillation and acute coronary syndromes: results of the European Heart Rhythm Association survey. <i>Europace</i> , 2019, 21, 1116-1125.	0.7	10
75	ICUSI questionnaire validation. Quality of anticoagulation in patients with atrial fibrillation treated with vitamin K antagonists. <i>REC: CardioClinics</i> , 2019, 54, 165-172.	0.1	3
76	Murcia atrial fibrillation project II: protocol for a prospective observational study in patients with atrial fibrillation. <i>BMJ Open</i> , 2019, 9, e033712.	0.8	3
77	Chronic Kidney Disease and Third-Generation P2Y <sub>12</sub> Inhibitors Use in Patients With Acute Coronary Syndrome: Impact on the Prognosis at 1 Year. <i>Journal of Clinical Pharmacology</i> , 2019, 59, 295-302.	1.0	2
78	Impact of anemia as risk factor for major bleeding and mortality in patients with acute coronary syndrome. <i>European Journal of Internal Medicine</i> , 2019, 61, 48-53.	1.0	19
79	Efficacy and safety of peri-procedural bridging therapy with low molecular weight heparin in atrial fibrillation patients under vitamin K antagonists. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2019, 112, 183-188.	0.2	3
80	Epidemiology of Cardiac Myxoma in a Spanish Population. A 30-year Surgical Series. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 685-686.	0.4	2
81	Invasive Versus Conservative Strategy in Frail Patients With NSTEMI: The MOSCA-FRIL Clinical Trial Study Design. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2019, 72, 154-159.	0.4	31
82	Under-prescription of novel antiplatelet drugs in patients with acute coronary syndrome and previous cardiovascular disease. <i>Minerva Medica</i> , 2019, 110, 410-418.	0.3	4
83	Riesgo embólico, riesgo isquémico y riesgo hemorrágico. <i>Revista Espanola De Cardiologia Suplementos</i> , 2019, 18, 3-8.	0.2	0
84	¿Existen lagunas en la evidencia vinculada al tratamiento de la hipertensión leve de bajo riesgo cardiovascular? Respuesta. <i>Revista Espanola De Cardiologia</i> , 2019, 72, 886.	0.6	0
85	Criteria for admitting elderly patients with acute coronary syndrome to critical care units from Spanish hospital emergency departments: a LONGEVO-SCA cohort study. <i>Emergencias</i> , 2019, 31, 154-160.	0.6	4
86	Disparities in the Estimation of Glomerular Filtration Rate According to Cockcroft-Gault, Modification of Diet in Renal Disease, and Chronic Kidney Disease Epidemiology Collaboration Equations and Relation With Outcomes in Patients With Acute Coronary Syndrome. <i>Journal of the American Heart Association</i> , 2018, 7, .	1.6	16
87	Optimizing Vitamin K Antagonist Treatment in Patients with Mechanical Heart Valve Prosthesis. <i>Thrombosis and Haemostasis</i> , 2018, 118, 806-807.	1.8	1
88	Contemporary stroke prevention strategies in 11% of European patients with atrial fibrillation: a report from the EURObservational Research Programme on Atrial Fibrillation (EORP-AF) Long-Term General Registry. <i>Europace</i> , 2018, 20, 747-757.	0.7	118
89	Antiplatelet therapy combined with acenocoumarol in relation to major bleeding, ischaemic stroke and mortality. <i>International Journal of Clinical Practice</i> , 2018, 72, e13069.	0.8	4
90	Quality of oral anticoagulation with vitamin K antagonists in "real-world" patients with atrial fibrillation: a report from the prospective multicentre FANTASIA registry. <i>Europace</i> , 2018, 20, 1435-1441.	0.7	39



#	ARTICLE	IF	CITATIONS
91	Reduced Time in Therapeutic Range and Higher Mortality in Atrial Fibrillation Patients Taking Acenocoumarol. <i>Clinical Therapeutics</i> , 2018, 40, 114-122.	1.1	21
92	Comentarios a la actualización ESC 2017 sobre el tratamiento antiagregante plaquetario doble en la enfermedad coronaria. <i>Revista Espanola De Cardiologia</i> , 2018, 71, 6-12.	0.6	2
93	Comments on the 2017 ESC Focused Update on Dual Antiplatelet Therapy in Coronary Artery Disease. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2018, 71, 6-12.	0.4	3
94	A Propensity Score Matched Comparison of Clinical Outcomes in Atrial Fibrillation Patients Taking Vitamin K Antagonists: Comparing the "Real-World" vs Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2018, 93, 1065-1073.	1.4	28
95	Soluble Fibrin Monomer Complex and Prediction of Cardiovascular Events in Atrial Fibrillation: The Observational Murcia Atrial Fibrillation Project. <i>Journal of General Internal Medicine</i> , 2018, 33, 847-854.	1.3	14
96	The future of nutrition: Nutrigenomics and nutrigenetics in obesity and cardiovascular diseases. <i>Critical Reviews in Food Science and Nutrition</i> , 2018, 58, 3030-3041.	5.4	54
97	Enhancing the "real world" prediction of cardiovascular events and major bleeding with the CHA <sub>2</sub> DS <sub>2</sub> -VASc and HAS-BLED scores using multiple biomarkers. <i>Annals of Medicine</i> , 2018, 50, 26-34.	1.5	22
98	Estimated absolute effects on efficacy and safety outcomes of using non-vitamin K antagonist oral anticoagulants in "real-world" atrial fibrillation patients: A comparison with optimally acenocoumarol anticoagulated patients. <i>International Journal of Cardiology</i> , 2018, 254, 125-131.	0.8	18
99	An Easy Assessment of Frailty at Baseline Independently Predicts Prognosis in Very Elderly Patients With Acute Coronary Syndromes. <i>Journal of the American Medical Directors Association</i> , 2018, 19, 296-303.	1.2	65
100	Temporal Trends in the Use of Antiplatelet Therapy in Patients With Acute Coronary Syndromes. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 2018, 23, 57-65.	1.0	21
101	115...Plods and lox participate in vascular smooth muscle cell calcification. , 2018, , .		0
102	Oral anticoagulation and comorbidities; too many details for clinical practice?. <i>International Journal of Cardiology</i> , 2018, 264, 93-94.	0.8	1
103	Comparison of the 2MACE and TIMI-AF Scores for Composite Clinical Outcomes in Anticoagulated Atrial Fibrillation Patients. <i>Circulation Journal</i> , 2018, 82, 1286-1292.	0.7	4
104	Inhibition of enzymes involved in collagen crosslinking reduces vascular smooth muscle cell calcification. <i>FASEB Journal</i> , 2018, 32, 4459-4469.	0.2	60
105	Estimated Effectiveness and Safety of Nonvitamin K Antagonist Oral Anticoagulants Compared With Optimally Acenocoumarol Anticoagulated "Real-World" in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2018, 122, 785-792.	0.7	12
106	Translating guidelines into practice for the management of atrial fibrillation: results of an European Heart Rhythm Association Survey. <i>Europace</i> , 2018, 20, 1382-1387.	0.7	15
107	Perioperative and Periprocedural Management of Antithrombotic Therapy: Consensus Document of SEC, SEDAR, SEACV, SECTCV, AEC, SECPRE, SEPD, SEGO, SEHH, SETH, SEMERGEN, SEMFYC, SEMG, SEMICYUC, SEMI, SEMES, SEPAR, SENEC, SEO, SEPA, SERVEL, SECOT and AEU. <i>Revista Espanola De Cardiologia (English)</i> TJ ETQq1 1 0.784314 rgBT	0.4	35
108	Invasive strategy and frailty in very elderly patients with acute coronary syndromes. <i>EuroIntervention</i> , 2018, 14, e336-e342.	1.4	46

#	ARTICLE	IF	CITATIONS
109	Intra-ventricular thrombus resolution after anticoagulation therapy with rivaroxaban in patient with poor anticoagulation quality. <i>Cardiology Journal</i> , 2018, 25, 151-154.	0.5	4
110	Anti-inflammatory effects of omega 3 and omega 6 polyunsaturated fatty acids in cardiovascular disease and metabolic syndrome. <i>Critical Reviews in Food Science and Nutrition</i> , 2017, 57, 3421-3429.	5.4	153
111	Evaluaci3n de los esquemas de riesgo hemorr3gico HAS-BLED y ORBIT en pacientes con fibrilaci3n auricular no valvular tratados con anticoagulaci3n oral. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 132-133.	0.6	0
112	Comentarios a la gu3a ESC 2016 sobre el diagn3stico y tratamiento de la fibrilaci3n auricular. <i>Revista Espanola De Cardiologia</i> , 2017, 70, 2-8.	0.6	11
113	Does von Willebrand factor improve the predictive ability of current risk stratification scores in patients with atrial fibrillation?. <i>Scientific Reports</i> , 2017, 7, 41565.	1.6	31
114	Galectin-3 as a marker of interstitial atrial remodelling involved in atrial fibrillation. <i>Scientific Reports</i> , 2017, 7, 40378.	1.6	48
115	Low body weight and clinical outcomes in acute coronary syndrome patients: results of the ACHILLES Registry. <i>European Journal of Cardiovascular Nursing</i> , 2017, 16, 696-703.	0.4	10
116	Hypertension and Cardiac Arrhythmias: Executive Summary of a Consensus Document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2017, 3, 235-250.	1.4	50
117	Hypertension and cardiac arrhythmias: a consensus document from the European Heart Rhythm Association (EHRA) and ESC Council on Hypertension, endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS) and Sociedad Latinoamericana de Estimulaci3n Card3aca y Electrofisiolog3a (SOLEACE). <i>Europace</i> , 2017, 19, 891-911.	0.7	124
118	Direct oral anticoagulants and cardiovascular prevention in patients with nonvalvular atrial fibrillation. <i>Expert Opinion on Pharmacotherapy</i> , 2017, 18, 67-77.	0.9	7
119	Deciphering acute coronary syndrome biomarkers: High-resolution proteomics in platelets, thrombi and microparticles. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2017, 54, 49-58.	2.7	15
120	Evaluation of HAS-BLED and ORBIT Bleeding Risk Scores in Nonvalvular Atrial Fibrillation Patients Receiving Oral Anticoagulants. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2017, 70, 132-133.	0.4	0
121	Usefulness of the 2MACE Score to Predicts Adverse Cardiovascular Events in Patients With Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2017, 120, 2176-2181.	0.7	19
122	Research update for articles published in EICI in 2015. <i>European Journal of Clinical Investigation</i> , 2017, 47, 775-788.	1.7	0
123	Importance of time in therapeutic range on bleeding risk prediction using clinical risk scores in patients with atrial fibrillation. <i>Scientific Reports</i> , 2017, 7, 12066.	1.6	16
124	Long-term Stroke Risk Prediction in Patients With Atrial Fibrillation: Comparison of the ABC2 Stroke and CHA2DS2-VASc Scores. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	42
125	Efficacy of non-vitamin-K antagonist oral anticoagulants for intracardiac thrombi resolution in nonvalvular atrial fibrillation. <i>Drug Discovery Today</i> , 2017, 22, 1565-1571.	3.2	6
126	Non-vitamin K antagonist oral anticoagulants: impact of non-adherence and discontinuation. <i>Expert Opinion on Drug Safety</i> , 2017, 16, 1051-1062.	1.0	24



#	ARTICLE	IF	CITATIONS
127	Applicability of the modified CHA <sub>2</sub> DS <sub>2</sub> -VASc score for stroke risk stratification in Caucasian atrial fibrillation patients. <i>European Journal of Internal Medicine</i> , 2017, 38, e21-e22.	1.0	5
128	Cessation of oral anticoagulation is an important risk factor for stroke and mortality in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1448-1454.	1.8	74
129	Assessing Bleeding Risk in Atrial Fibrillation Patients: Comparing a Bleeding Risk Score Based Only on Modifiable Bleeding Risk Factors against the HAS-BLED Score. The AMADEUS Trial. <i>Thrombosis and Haemostasis</i> , 2017, 117, 2261-2266.	1.8	51
130	Long-term bleeding risk prediction in "real world"™ patients with atrial fibrillation: Comparison of the HAS-BLED and ABC-Bleeding risk scores. <i>Thrombosis and Haemostasis</i> , 2017, 117, 1848-1858.	1.8	56
131	Therapeutic management and one-year outcomes in elderly patients with acute coronary syndrome. <i>Oncotarget</i> , 2017, 8, 80182-80191.	0.8	12
132	New Approaches to the Role of Thrombin in Acute Coronary Syndromes: Quo Vadis Bivalirudin, a Direct Thrombin Inhibitor?. <i>Molecules</i> , 2016, 21, 284.	1.7	2
133	Clinical implications of nonsarcomeric gene polymorphisms in hypertrophic cardiomyopathy. <i>European Journal of Clinical Investigation</i> , 2016, 46, 123-129.	1.7	1
134	Strategies for prediction and early detection of atrial fibrillation: present and future. <i>Europace</i> , 2016, 19, euw131.	0.7	3
135	Platelet reactivity over time in coronary artery disease patients treated with a bioabsorbable everolimus-eluting scaffold. <i>Platelets</i> , 2016, 27, 777-783.	1.1	5
136	Comparison of Risk Prediction With the <sc>CKD&EPI</sc> and <sc>MDRD</sc> Equations in Non&lt;sc>ST</sc>&lt;sc>Segment Elevation Acute Coronary Syndrome. <i>Clinical Cardiology</i> , 2016, 39, 507-515.	0.7	17
137	En el camino de un mejor uso de los anticoagulantes en la fibrilaci3n auricular no valvular. Propuesta de modificaci3n del posicionamiento terap&#oacute;tico UT/V4/23122013. <i>Revista Espanola De Cardiologia</i> , 2016, 69, 551-553.	0.6	28
138	On the Way to a Better Use of Anticoagulants in Nonvalvular Atrial Fibrillation. Proposed Amendment to the Therapeutic Positioning Report UT/V4/23122013. <i>Revista Espanola De Cardiologia (English Ed)</i> , 2016, 69, 551-553.	0.4	10
139	The HAS-BLED score predicts long-term major bleeding and death in anticoagulated non-valvular atrial fibrillation patients undergoing electrical cardioversion. <i>International Journal of Cardiology</i> , 2016, 217, 42-48.	0.8	6
140	New Role of Biomarkers in Atrial Fibrillation. , 2016, , 507-539.		0
141	Is oral anticoagulation needed in patients with atrial fibrillation and stent implantation at low&lt;sc>moderate risk of stroke?. <i>European Journal of Internal Medicine</i> , 2016, 35, e9-e10.	1.0	2
142	Long-Term Predictors of Thromboembolic Events in Nonvalvular Atrial Fibrillation Patients Undergoing Electrical Cardioversion. <i>Circulation Journal</i> , 2016, 80, 605-612.	0.7	5
143	Is the ORBIT Bleeding Risk Score Superior to the HAS-BLED Score in Anticoagulated Atrial Fibrillation Patients?. <i>Circulation Journal</i> , 2016, 80, 2102-2108.	0.7	21
144	Randomized comparison between the invasive and conservative strategies in comorbid elderly patients with non-ST elevation myocardial infarction. <i>European Journal of Internal Medicine</i> , 2016, 35, 89-94.	1.0	68

#	ARTICLE	IF	CITATIONS
145	Do physicians correctly calculate thromboembolic risk scores? A comparison of concordance between manual and computer-based calculation of CHADS <sub>2</sub> and CHA <sub>2</sub> DS <sub>2</sub> -VASc scores. Internal Medicine Journal, 2016, 46, 583-589.	0.5	1
146	Von Willebrand factor is associated with atrial fibrillation development in ischaemic patients after cardiac surgery. Europace, 2016, 18, 1328-1334.	0.7	5
147	The SAME-TT2R2 score and decision-making between a vitamin K antagonist or a non-vitamin K antagonist oral anticoagulant in patients with atrial fibrillation. Expert Review of Cardiovascular Therapy, 2016, 14, 177-187.	0.6	18
148	Tratamiento antiarrátmico actual de la fibrilación auricular no valvular en España. Datos del Registro FANTASIA. Revista Espanola De Cardiologia, 2016, 69, 54-60.	0.6	20
149	miRNA-197 and miRNA-223 and cardiovascular death in coronary artery disease patients. Annals of Translational Medicine, 2016, 4, 200-200.	0.7	6
150	sST2 levels are associated with all-cause mortality in anticoagulated patients with atrial fibrillation. European Journal of Clinical Investigation, 2015, 45, 899-905.	1.7	19
151	Major bleeding risk prediction using Chronic Kidney Disease Epidemiology Collaboration and Modification of Diet in Renal Disease equations in acute coronary syndrome. European Journal of Clinical Investigation, 2015, 45, 385-393.	1.7	6
152	Effects of Body Mass Index on the Lipid Profile and Biomarkers of Inflammation and a Fibrinolytic and Prothrombotic State. Journal of Atherosclerosis and Thrombosis, 2015, 22, 610-617.	0.9	19
153	The importance of excellence in the quality of anticoagulation control whilst taking vitamin K antagonists. Thrombosis and Haemostasis, 2015, 113, 671-673.	1.8	19
154	Quality of Anticoagulation With Vitamin K Antagonists. Clinical Cardiology, 2015, 38, 357-364.	0.7	67
155	The SAME-TT2R2 Score Predicts Poor Anticoagulation Control in AF Patients: A Prospective "Real-world" Inception Cohort Study. American Journal of Medicine, 2015, 128, 1237-1243.	0.6	51
156	CALU polymorphism A29809G affects calumenin availability involving vascular calcification. Journal of Molecular and Cellular Cardiology, 2015, 82, 218-227.	0.9	11
157	Clinical development of rivaroxaban: emerging new clinical evidences?. Future Cardiology, 2015, 11, 565-583.	0.5	0
158	Comparison of Estimated Glomerular Filtration Rate Equations for Dosing New Oral Anticoagulants in Patients With Atrial Fibrillation. Revista Espanola De Cardiologia (English Ed ), 2015, 68, 497-504.	0.4	17
159	Involvement of the <i>RETN</i> polymorphism in myocardial fibrosis in patients with hypertrophic cardiomyopathy. Journal of Internal Medicine, 2015, 278, 50-58.	2.7	5
160	GDF-15 and risk stratification in atrial fibrillation. Nature Reviews Cardiology, 2015, 12, 8-9.	6.1	18
161	Novel biomarkers in cardiology: MicroRNAs in atrial fibrillation. Archivos De Cardiologia De Mexico, 2015, 85, 225-229.	0.1	10
162	A comprehensive insight of novel antioxidant therapies for atrial fibrillation management. Drug Metabolism Reviews, 2015, 47, 388-400.	1.5	13

#	ARTICLE	IF	CITATIONS
163	Biomarkers of Necrosis and Myocardial Remodeling. Biomarkers in Disease, 2015, , 659-688.	0.0	0
164	New Role of Biomarkers in Atrial Fibrillation. , 2015, , 1-33.		1
165	Prognostic role of MIR146A polymorphisms for cardiovascular events in atrial fibrillation. Thrombosis and Haemostasis, 2014, 112, 781-788.	1.8	36
166	Prognostic value of two polymorphisms in non-sarcomeric genes for the development of atrial fibrillation in patients with hypertrophic cardiomyopathy. QJM - Monthly Journal of the Association of Physicians, 2014, 107, 613-621.	0.2	14
167	Usefulness of N-Terminal Pro-B-Type Natriuretic Peptide Levels for Stroke Risk Prediction in Anticoagulated Patients With Atrial Fibrillation. Stroke, 2014, 45, 696-701.	1.0	39
168	Biomarkers in atrial fibrillation: an overview. International Journal of Clinical Practice, 2014, 68, 434-443.	0.8	37
169	Management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous coronary or valve interventions: a joint consensus document of the European Society of Cardiology Working Group on Thrombosis, European Heart Rhythm Association (EHRA), European Association of Percutaneous Cardiovascular Interventions (EAPCI) and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS) and Asia-Pacific Heart Rhythm So. European Heart Journal, 2014, 35, 3155-3179.	1.0	490
170	Update on Ischemic Heart Disease and Critical Care Cardiology. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 120-126.	0.4	3
171	Estratificaci3n pron3stica din3mica en el infarto agudo de miocardio con elevaci3n del segmento ST. Respuesta. Revista Espanola De Cardiologia, 2014, 67, 588.	0.6	0
172	SAME-TT2R2 Score, Time in Therapeutic Range, and Outcomes in Anticoagulated Patients with Atrial Fibrillation. American Journal of Medicine, 2014, 127, 1083-1088.	0.6	112
173	Dynamic Prognostic Stratification in ST-elevation Myocardial Infarction. Response. Revista Espanola De Cardiologia (English Ed ), 2014, 67, 588.	0.4	0
174	The optimal management of patients on oral anticoagulation undergoing coronary artery stenting. Thrombosis and Haemostasis, 2014, 112, 1080-1087.	1.8	60
175	Biomarkers of Necrosis and Myocardial Remodeling. , 2014, , 1-24.		1
176	Lone Atrial Fibrillation- A Diagnosis of Exclusion. Current Pharmaceutical Design, 2014, 21, 544-550.	0.9	3
177	Renal Impairment in a Real-Life Cohort of Anticoagulated Patients With Atrial Fibrillation (Implications for Thromboembolism and Bleeding). American Journal of Cardiology, 2013, 111, 1159-1164.	0.7	110
178	The HAS-BLED Score Has Better Prediction Accuracy for Major Bleeding Than CHADS2 or CHA2DS2-VASc Scores in Anticoagulated Patients With Atrial Fibrillation. Journal of the American College of Cardiology, 2013, 62, 2199-2204.	1.2	171
179	N-terminal Pro-brain Natriuretic Peptide and High-sensitivity Troponin in the Evaluation of Acute Chest Pain of Uncertain Etiology. A PITAGORAS Substudy. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 532-538.	0.4	2
180	Interleukin-6 and High-sensitivity C-reactive Protein for the Prediction of Outcomes in Non-ST-segment Elevation Acute Coronary Syndromes. Revista Espanola De Cardiologia (English Ed ), 2013, 66, 185-192.	0.4	11

#	ARTICLE	IF	CITATIONS
181	Interleucina 6 y proteÃnina C reactiva ultrasensible para la predicciÃ³n de la evoluciÃ³n clÃnica en sÃndromes coronarios agudos sin elevaciÃ³n del segmento ST. Revista Espanola De Cardiologia, 2013, 66, 185-192.	0.6	12
182	The prognostic role of the adiponectin levels in atrial fibrillation. European Journal of Clinical Investigation, 2013, 43, 168-173.	1.7	20
183	Comparative Determination and Monitoring of Biomarkers of Necrosis and Myocardial Remodeling between Radiofrequency Ablation and Cryoablation. PACE - Pacing and Clinical Electrophysiology, 2013, 36, 31-36.	0.5	11
184	Antithrombotic therapy and bleeding risk in atrial fibrillation. Fewer unanswered questions. Thrombosis and Haemostasis, 2013, 109, 363-365.	1.8	2
185	Predictive Value of the HAS-BLED and ATRIA Bleeding Scores for the Risk of Serious Bleeding in a â€œReal-Worldâ€ Population With Atrial Fibrillation Receiving Anticoagulant Therapy. Chest, 2013, 143, 179-184.	0.4	176
186	Small-size circulating microparticles in acute coronary syndromes: Relevance to fibrinolytic status, reparative markers and outcomes. Atherosclerosis, 2013, 227, 313-322.	0.4	87
187	FracciÃ³n aminoterminal del propÃ©ptido natriurÃ©tico cerebral y troponina ultrasensible en el dolor torÃ¡cico agudo de origen incierto. Un subestudio del estudio PITAGORAS. Revista Espanola De Cardiologia, 2013, 66, 532-538.	0.6	8
188	Î²-Trace Protein: From GFR Marker to Cardiovascular Risk Predictor. Clinical Journal of the American Society of Nephrology: CJASN, 2013, 8, 873-881.	2.2	32
189	The complex role of bone turnover biomarkers in cardiovascular diseases. European Journal of Heart Failure, 2013, 15, 709-710.	2.9	0
190	Beta-Trace Protein and Cystatin C as Predictors of Major Bleeding in Non-ST-Segment Elevation Acute Coronary Syndrome. Circulation Journal, 2013, 77, 2088-2096.	0.7	6
191	Cessation of oral anticoagulation in relation to mortality and the risk of thrombotic events in patients with atrial fibrillation. Thrombosis and Haemostasis, 2013, 110, 1189-1198.	1.8	182
192	Î²-Trace Protein and Prognosis in Patients With Atrial Fibrillation Receiving Anticoagulation Treatment. Chest, 2013, 144, 1564-1570.	0.4	12
193	Antithrombotic therapy in atrial fibrillation and stent implantation: treatment or threats by the use of triple or dual antithrombotic therapy. Thrombosis and Haemostasis, 2013, 110, 623-625.	1.8	11
194	Does chronic kidney disease improve the predictive value of the CHADS2 and CHA2DS2-VASc stroke stratification risk scores for atrial fibrillation?. Thrombosis and Haemostasis, 2013, 109, 956-960.	1.8	102
195	Should We Recommend Oral Anticoagulation Therapy in Patients With Atrial Fibrillation Undergoing Coronary Artery Stenting With a High HAS-BLED Bleeding Risk Score?. Circulation: Cardiovascular Interventions, 2012, 5, 459-466.	1.4	60
196	Relation of the HAS-BLED Bleeding Risk Score to Major Bleeding, Cardiovascular Events, and Mortality in Anticoagulated Patients With Atrial Fibrillation. Circulation: Arrhythmia and Electrophysiology, 2012, 5, 312-318.	2.1	123
197	Pre and Post-Operative Treatments for Prevention of Atrial Fibrillation after Cardiac Surgery. Mini-Reviews in Medicinal Chemistry, 2012, 12, 1419-1431.	1.1	0
198	High sensitivity cardiac troponin T and interleukinâ€6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation. Journal of Thrombosis and Haemostasis, 2012, 10, 1500-1507.	1.9	97

#	ARTICLE	IF	CITATIONS
199	Predictive Value of the CHA2DS2-VASc Score in Atrial Fibrillation Patients at High Risk for Stroke Despite Oral Anticoagulation. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2012, 65, 627-633.	0.4	14
200	Nuevas evidencias, nuevas controversias: análisis crítico de la guía de práctica clínica sobre fibrilación auricular 2010 de la Sociedad Europea de Cardiología. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 7-13.	0.6	26
201	Valor predictivo de la escala CHA2DS2-VASc en pacientes con fibrilación auricular de alto riesgo embólico en tratamiento anticoagulante. <i>Revista Espanola De Cardiologia</i> , 2012, 65, 627-633.	0.6	41
202	Growth differentiation factor-15, a novel biomarker related with disease severity in patients with hypertrophic cardiomyopathy. <i>European Journal of Internal Medicine</i> , 2012, 23, 169-174.	1.0	45
203	Ankle brachial index as an independent predictor of mortality in anticoagulated atrial fibrillation. <i>European Journal of Clinical Investigation</i> , 2012, 42, 1302-1308.	1.7	21
204	High sensitivity cardiac troponin T and interleukin-6 predict adverse cardiovascular events and mortality in anticoagulated patients with atrial fibrillation: a reply to a rebuttal. <i>Journal of Thrombosis and Haemostasis</i> , 2012, 10, 2414-2415.	1.9	3
205	Mild kidney disease as a risk factor for major bleeding in patients with atrial fibrillation undergoing percutaneous coronary stenting. <i>Thrombosis and Haemostasis</i> , 2012, 107, 51-58.	1.8	13
206	Plasma von Willebrand Factor Levels Are an Independent Risk Factor for Adverse Events Including Mortality and Major Bleeding in Anticoagulated Atrial Fibrillation Patients. <i>Journal of the American College of Cardiology</i> , 2011, 57, 2496-2504.	1.2	121
207	Is plasminogen activator inhibitor-1 (PAI-1) a surrogate marker of vascular damage?. <i>Thrombosis Research</i> , 2011, 128, 601-602.	0.8	1
208	Antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting: Similarities and dissimilarities between North America and Europe. <i>Thrombosis and Haemostasis</i> , 2011, 106, 569-571.	1.8	70
209	Bleeding risk assessment and management in atrial fibrillation patients. <i>Thrombosis and Haemostasis</i> , 2011, 106, 997-1011..	1.8	234
210	Circulating microparticles: new insights into the biochemical basis of microparticle release and activity. <i>Basic Research in Cardiology</i> , 2011, 106, 911-923.	2.5	80
211	Collagen peptides, interstitial remodelling and sudden cardiac death in hypertrophic cardiomyopathy. <i>Clinical Chemistry and Laboratory Medicine</i> , 2011, 49, 1569-71.	1.4	6
212	Impact of polymorphisms in the renin-angiotensin-aldosterone system on hypertrophic cardiomyopathy. <i>JRAAS - Journal of the Renin-Angiotensin-Aldosterone System</i> , 2011, 12, 521-530.	1.0	20
213	An Evaluation of the CHADS 2 Stroke Risk Score in Patients With Atrial Fibrillation Who Undergo Percutaneous Coronary Revascularization. <i>Chest</i> , 2011, 139, 1402-1409.	0.4	15
214	Bleeding risk assessment and management in atrial fibrillation patients: a position document from the European Heart Rhythm Association, endorsed by the European Society of Cardiology Working Group on Thrombosis. <i>Europace</i> , 2011, 13, 723-746.	0.7	197
215	An Insight of Novel Pharmacological Therapies in Hypertrophic Cardiomyopathy. <i>Medicinal Chemistry</i> , 2011, 7, 275-285.	0.7	10
216	Estratificación del riesgo hemorrágico en el síndrome coronario agudo. <i>Revista Espanola De Cardiologia Suplementos</i> , 2010, 10, 49-58.	0.2	2

#	ARTICLE	IF	CITATIONS
217	Antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI). <i>European Heart Journal</i> , 2010, 31, 1311-1318.	1.0	216
218	Genetic polymorphisms and atrial fibrillation: Insights into the prothrombotic state and thromboembolic risk. <i>Annals of Medicine</i> , 2010, 42, 562-575.	1.5	10
219	Management of Antithrombotic Therapy in Atrial Fibrillation Patients Presenting with Acute Coronary Syndrome and/or Undergoing Percutaneous Coronary Intervention/ Stenting. <i>Thrombosis and Haemostasis</i> , 2010, 103, 13-28.	1.8	292
220	Effects of atorvastatin 80Âmg daily on indices of matrix remodelling in â€˜high-riskâ€™™ patients with ischemic heart disease. <i>International Journal of Cardiology</i> , 2010, 139, 95-97.	0.8	6
221	CALU A29809G polymorphism in coronary atherothrombosis: Implications for coronary calcification and prognosis. <i>Annals of Medicine</i> , 2010, 42, 439-446.	1.5	12
222	Left atrial remodelling in hypertrophic cardiomyopathy: relation with exercise capacity and biochemical markers of tissue strain and remodelling. <i>International Journal of Clinical Practice</i> , 2009, 63, 1465-1471.	0.8	23
223	Influence of electrical cardioversion on inflammation and indexes of structural remodeling, in persistent atrial fibrillation. <i>International Journal of Cardiology</i> , 2009, 132, 227-232.	0.8	13
224	Matrix metalloproteinases and tissue remodeling in hypertrophic cardiomyopathy. <i>American Heart Journal</i> , 2008, 156, 85-91.	1.2	80
225	Variables Associated With Contrast-Enhanced Cardiovascular Magnetic Resonance in Hypertrophic Cardiomyopathy: Clinical Implications. <i>Journal of Cardiac Failure</i> , 2008, 14, 414-419.	0.7	33
226	Factor VII â€“323 decanucleotide D/I polymorphism in atrial fibrillation: Implications for the prothrombotic state and stroke risk. <i>Annals of Medicine</i> , 2008, 40, 553-559.	1.5	14
227	The impact of statin use on atrial fibrillation. <i>QJM - Monthly Journal of the Association of Physicians</i> , 2008, 101, 845-861.	0.2	25
228	Increased Major Bleeding Complications Related to Triple Antithrombotic Therapy Usage in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Artery Stenting. <i>Chest</i> , 2008, 134, 559-567.	0.4	117
229	Efficacy and safety of drug-eluting stent use in patients with atrial fibrillation. <i>European Heart Journal</i> , 2008, 30, 932-939.	1.0	44
230	A multimarker risk stratification approach to nonâ€“ST elevation acute coronary syndrome: implications of troponin T, CRP, NT proâ€“BNP and fibrin Dâ€“dimer levels. <i>Journal of Internal Medicine</i> , 2007, 262, 651-658.	2.7	87
231	The pharmacogenetics of antiplatelet drugs. <i>Current Opinion in Investigational Drugs</i> , 2007, 8, 213-8.	2.3	4
232	Implantable Cardioverter Defibrillator and Hypertrophic Cardiomyopathy. Experience at Three Centers. <i>Revista Espanola De Cardiologia (English Ed )</i> , 2006, 59, 537-544.	0.4	11
233	Does smoking status influence the effect of physical exercise on fibrinolytic function in healthy volunteers?. <i>Journal of Thrombosis and Thrombolysis</i> , 2006, 21, 163-166.	1.0	4
234	Statins and Postoperative Risk of Atrial Fibrillation Following Coronary Artery Bypass Grafting. <i>American Journal of Cardiology</i> , 2006, 97, 55-60.	0.7	204



#	ARTICLE	IF	CITATIONS
235	Effect of Statins on Preventing Recurrence of Atrial Fibrillation After Electrical Cardioversion. American Journal of Cardiology, 2006, 98, 1299-1300.	0.7	23
236	Pharmacogenetics in Cardiovascular Antithrombotic Therapy. Current Medicinal Chemistry Cardiovascular and Hematological Agents, 2005, 3, 357-364.	1.7	4
237	Influence of smoking habit on cardiac functional capacity and diastolic function in healthy people. International Journal of Cardiology, 2005, 98, 517-518.	0.8	5
238	Effect of Maximum Dose of Atorvastatin on Inflammation, Thrombogenesis, and Fibrinolysis in High-Risk Patients With Ischemic Heart Disease. Revista Espanola De Cardiologia (English Ed ), 2005, 58, 934-940.	0.4	4
239	Plasma von Willebrand factor, soluble thrombomodulin, and fibrin D-dimer concentrations in acute onset non-rheumatic atrial fibrillation. Heart, 2004, 90, 1162-1166.	1.2	80
240	¿Podemos esperar de los polimorfismos las respuestas a nuestras dudas?. Revista Espanola De Cardiologia, 2004, 57, 1129.	0.6	0
241	Can We Expect Polymorphisms to Answer our Questions?. Revista Espanola De Cardiologia (English Ed )	1.0	0
242	Factor XIII Val34Leu polymorphism modulates the prothrombotic and inflammatory state associated with atrial fibrillation. Journal of Molecular and Cellular Cardiology, 2004, 37, 699-704.	0.9	36
243	Short alleles of P-selectin glycoprotein ligand-1 protect against premature myocardial infarction. American Heart Journal, 2004, 148, 602-605.	1.2	18
244	Interleukin-6, endothelial activation and thrombogenesis in chronic atrial fibrillation. European Heart Journal, 2003, 24, 1373-1380.	1.0	118
245	Fibrinolytic function and atrial fibrillation. Thrombosis Research, 2003, 109, 233-240.	0.8	34
246	Is Thrombogenesis in Atrial Fibrillation Related to Matrix Metalloproteinase-1 and Its Inhibitor, TIMP-1?. Stroke, 2003, 34, 1181-1186.	1.0	93
247	Relation of Maximal Doses of Atorvastatin to Indices of Inflammation, Thrombogenesis and Angiogenesis in High-Risk Patients with Ischemic Heart Disease. Clinical Science, 2003, 104, 9P-9P.	0.0	0
248	The role of tissue plasminogen activator on the progression of the coronary disease. European Heart Journal, 2002, 23, 88.	1.0	5
249	Prothrombotic state and elevated levels of plasminogen activator inhibitor-1 in mitral stenosis with and without atrial fibrillation. American Journal of Cardiology, 1999, 84, 862-864.	0.7	24
250	Hypofibrinolysis in atrial fibrillation. American Heart Journal, 1998, 136, 956-960.	1.2	59
251	Morphological Fate of Rhombomeres in Quail/Chick Chimeras: A Segmental Analysis of Hindbrain Nuclei. European Journal of Neuroscience, 1995, 7, 1714-1738.	1.2	280
252	Patterning of the Embryonic Avian Midbrain after Experimental Inversions: A Polarizing Activity from the Isthmus. Developmental Biology, 1994, 163, 19-37.	0.9	190

#	ARTICLE	IF	CITATIONS
253	Impact of anthropometric factors on outcomes in atrial fibrillation patients: analysis on 10â€™220 patients from the European Society of Cardiology (ESC)-European Heart Rhythm Association (EHRA) EurObservational Research Programme on Atrial Fibrillation (EORP-AF) general long-term registry. European Journal of Preventive Cardiology, 0, , ,	0.8	3